Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: A phase 2 clinical trial in Uganda
Journal of Infectious Diseases, Volume 191, No. 6, Year 2005
Notification
URL copied to clipboard!
Description
Background. Human immunodeficiency virus (HIV)-infected patients with tuberculosis (TB) respond to effective antituberculous therapy, but their prognosis remains poor. Mounting evidence from clinical studies supports the concept of copathogenesis in which immune activation that is triggered by TB and mediated by cytokines stimulates viral replication and worsens HIV infection, especially when immune function is preserved. Methods. We performed a phase 2, randomized, double-blind, placebo-controlled clinical trial in Kampala, Uganda, to determine whether immunoadjuvant prednisolone therapy in HIV-infected patients with TB who have CD4+ T cell counts ≥200 cells/μL is safe and effective at increasing CD4+ T cell counts. Results. Short-term prednisolone therapy reduced levels of immune activation and tended to produce higher CD4+ T cell counts. Although prednisolone therapy was associated with a more rapid clearance of Mycobacterium tuberculosis from the sputum, it was also associated with a transient increase in HIV RNA levels, which receded when prednisolone therapy was discontinued. The intervention worsened underlying hypertension and caused fluid retention and hyperglycemia. Conclusion. The benefits of prednisolone therapy on immune activation and CD4+ T cell counts do not outweigh the risks of adverse events in HIV-infected patients with TB and preserved immune function. © 2005 by the Infectious Diseases Society of America. All rights reserved.
Authors & Co-Authors
Mayanja-Kizza, Harriet
Uganda, Kampala
School of Medicine, Makerere University College of Health Sciences
Jones-López, Edward C.
United States, Newark
Rutgers Biomedical and Health Sciences
Okwera, Alphonse
Uganda, Kampala
Natl. tb and Leprosy Contr. Prog.
Wallis, Robert S.
United States, Newark
Rutgers Biomedical and Health Sciences
Ellner, Jerrold J.
United States, Newark
Rutgers Biomedical and Health Sciences
Mugerwa, Roy D.
Uganda, Kampala
School of Medicine, Makerere University College of Health Sciences
Whalen, Christopher Curtis
United States, Cleveland
Case Western Reserve University
Statistics
Citations: 130
Authors: 7
Affiliations: 4
Identifiers
Doi:
10.1086/427995
ISSN:
00221899
Research Areas
Disability
Infectious Diseases
Noncommunicable Diseases
Study Design
Randomised Control Trial
Study Locations
Uganda